MarcusRebelloPereiraMD
Infectious Disease • New York, NYAssociate Professor, Medicine, Columbia University College of Phys & Surg
Overview of Dr. Pereira
Dr. Marcus Pereira is an infectious disease specialist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and NewYork-Presbyterian/Allen Hospital. He received his medical degree from University of Florida College of Medicine and has been in practice 13 years. He is one of 142 doctors at New York-Presbyterian Hospital and one of 45 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Infectious Disease. He has more than 60 publications and over 500 citings.
Office
180 Fort Washington Avenue
New York, NY 10032
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Infectious Disease, 2007 - 2009- New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2004 - 2007
University of Florida College of MedicineClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 1977 - 2025
NY State Medical License 2004 - 2025- NY State Medical License 2006 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients Start of enrollment: 2019 Jan 04
Roles: Contact, Principal Investigator
- Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients Start of enrollment: 2015 Nov 01
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 230 citationsAcute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort.Meaghan Phipps, Luis Barraza, Elijah LaSota, Magdalena E. Sobieszczyk, Marcus R. Pereira
Hepatology. 2020-09-01 - 134 citationsMaribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: A randomized, dose-ranging, double-blind, ...Genovefa A. Papanicolaou, Fernanda P. Silveira, Amelia Langston, Marcus R. Pereira, Robin K. Avery
Clinical Infectious Diseases. 2019-04-08 - 28 citationsDrug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.Sunwen Chou, Sophie Alain, Carlos Cervera, Roy F Chemaly, Camille N Kotton
The Journal of Infectious Diseases. 2024-02-14
Press Mentions
Kidney Transplantation Between Those with HIV Infections Shown Safe & EffectiveOctober 17th, 2024- The U.S. Is in a Fifth COVID Wave, and for Many, Immunity Is Waning. Why Aren’t Second Boosters Available to All Americans?May 14th, 2022
- Maribavir Rescue Therapy Effective for Cytomegalovirus Infection Post-TransplantApril 19th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
